Autologous or allogeneic transplantation in B- and T-cell lymphomas

The roles of HDT/autoSCT and alloSCT in the treatment of B- and T-cell lymphomas continue to change. With the wider use of Rituximab in virtually every patient with B-cell lymphoma transplantation as part of first-line therapy has been challenged. New studies fail to show a benefit of HDT/autoSCT ov...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical haematology 2012-03, Vol.25 (1), p.61-73
Main Authors: Schmitz, N., MD, PhD, Nickelsen, M., MD, Glaß, B., MD, PhD
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
B- and T-cell lymphomas treatment
Cyclophosphamide - administration & dosage
Cyclophosphamide - therapeutic use
Doxorubicin - administration & dosage
Doxorubicin - therapeutic use
Female
Hematology, Oncology and Palliative Medicine
Humans
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell - therapy
Lymphoma, T-Cell - pathology
Lymphoma, T-Cell - therapy
Male
Middle Aged
Prednisone - administration & dosage
Prednisone - therapeutic use
Randomized Controlled Trials as Topic
Recurrence
Rituximab
Salvage Therapy
Stem Cell Transplantation - utilization
Transplantation, Autologous
Transplantation, Homologous
Vincristine - administration & dosage
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The roles of HDT/autoSCT and alloSCT in the treatment of B- and T-cell lymphomas continue to change. With the wider use of Rituximab in virtually every patient with B-cell lymphoma transplantation as part of first-line therapy has been challenged. New studies fail to show a benefit of HDT/autoSCT over conventional therapy when administered to newly diagnosed patients with aggressive B-cell lymphoma; in the other B-cell lymphomas results from randomized studies are not yet available. Patients relapsing from first-line therapy including Rituximab do not have satisfying results with HDT/autoSCT. Therefore, alloSCT is increasingly being considered. In T-cell lymphoma the efficacy of autoSCT seems rather limited. Study groups and single institutions are developing new strategies including alloSCT to improve the situation for such patients both in the setting of first-line and salvage therapy.
ISSN:1521-6926
1532-1924
DOI:10.1016/j.beha.2012.01.007